the aid library

LIST OPTIONS

Filter

4776

Sort by:

Direction:

Download (2024)

View PDF (1469)

Clinic Supervisor Manual

Management Sciences for Health; USAID (2006) C1

This Clinic Supervisor’s Manual is helpful for focusing managers on the key elements of integrated primary health care as they simultaneously integrate new interventions for HIV/AIDS, tuberculosis, and malaria. This tool contains 12 sections. Section 1 explains how to use the manual. Section 2 hel... more

Download (716)

View PDF (1288)

A practical handbook on the pharmacovigilance of antiretroviral medicines

World Health Organization WHO (2013) C_WHO

This is a detailed manual giving a step by step approach to undertaking the pharmacovigilance of antiretrovirals. It is intended to be a source of practical advice for Pharmacovigilance Centres and health professionals involved in HIV/AIDS prevention and treatment programmes. A number of WHO publica... more

Download (202)

View PDF (392)

Networking for Policy Change An Advocacy Training Manual

Stop TB Partnership; World Health Organization; Constella Futures (2007) C_WHO

WHO/HTM/TB/2007.384a “TB is too often a death sentence for people with AIDS. It does not have to be this way.” -Nelson Mandela, International conference on HIV /AIDS, Bangkok, Thailand, July 2004

Download (219)

View PDF (511)

European Union Standards for Tuberculosis Care 2017 Update
recommended

European Centre for Disease Prevention and Control ECDC (2018) CC

The update of the ESTC was conducted as a joint endeavour with ERS, consulting experts from international societies and organisations, national TB programmes, civil society and affected communities. The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and co... more

Download (1491)

View PDF (1893)

PIH Guide to the Medical Management of MDR-TB

USAID; TB Care; DRTB Training Network (2014) C1

This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.

Download (446)

View PDF (278)

Standard Operating Procedures on Viral Load Monitoring for ICAP Clinical Staff and Health Care Workers: A Template Document for Country Adaptation

ICAP (2016) C1

Version 1.1 July 2016
The purpose of this document is to describe standard operating procedures for viral load monitoring, including the schedule for viral load testing when used for routine monitoring of children, adolescents and adults on ART; interpretation of results; patient management; an... more

Download (401)

View PDF (890)

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
recommended

World Health Organization WHO (2018) C_WHO

The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.

Download (471)

View PDF (319)

Management of Diabetes Mellitus-Tuberculosis
recommended

Lin, Y., et al. The Union (2019) C1

1st edition This resource provides practical guidance for front line health workers responsible for the diagnosis, management and care of patients with these two diseases. Published in collaboration with the World Diabetes Foundation

Download (151)

View PDF (218)

Information and Advice for the Home: Be coronavirus safe
recommended

Knowledge Translation Unit, University of Cape Town Lung Institute Western Cape Department of Health (2021) CC

Manual 1. The Practical Approach to Care Kit – PACK – is used by nurses, doctors and community health workers in their everyday work to care for patients at the clinic and in the community –PACK Adult, PACK Adolescent, PACK Child and PACK Community.PACK Home is designed for people seeking more... more

Download (108)

View PDF (95)

WHO guideline: the use of safety-engineered syringes for intramuscular, intradermal and subcutaneous injections in health care settings

World Health Organization WHO (2016) C_WHO

Injection practices worldwide and especially in low- and middle-income countries (LMICs) include multiple, avoidable unsafe practices that ultimately lead to the large-scale transmission of bloodborne viruses among patients, health care providers and the community at large.

Download (89)

View PDF (97)

Administration of Nirmatrelvir-ritonavir for COVID-19
recommended

World Health Organization WHO (2022) C_WHO

This series of supportive tools are based on the WHO Therapeutics and COVID-19: living guideline. They are intended to provide supportive information for healthcare workers who are prescribing, administering and monitoring patients receiving nirmatrelvir-ritonavir for non-severe COVID-19.

Download (136)

View PDF (160)

Botswana National Integration Guidelines

United Nations Population Fund UNFPA (2022) C1

This Guideline, the first for the country, draws from national health sector reforms and integration agenda as outlined in the key national strategic documents. The Guide applies lessons learnt from the SRH/HIV Linkages project and its scale-up; other national experiences and from regional and globa... more

Download (124)

View PDF (140)

Framework for collaborative action on tuberculosis and comorbidities

World Health Organization WHO (2022) C_WHO

Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun... more

Download (162)

View PDF (178)

Global leishmaniasis surveillance: 2021, assessing the impact of the COVID-19 pandemic

Ruiz-Postigo, J.A.; et al. World Health Organization WHO (2022) C_WHO

Surveillance mondiale de la leishmaniose: 2021, évaluation de l’impact de la pandémie de COVID-19 The aims of this report are to update the results of the GHO leishmaniasis indicators reported by Member States to WHO up to 2021, to describe specific indicators of gender and age distribution, re... more

Download (109)

View PDF (141)

Data for impact_ How UNADIS data is guiding the world to end AIDS

UNAIDS (2022) C_WHO

As part of the UN’s data strategy—which seeks to nurture data as a strategic asset for insight, impact and integrity—UNAIDS plays an indispensable role in generating data for effective action against the AIDS pandemic. It leads the world’s most extensive data collection on HIV epidemiology,... more

Download (91)

View PDF (116)

Target product profile for readers of rapid diagnostic tests

World Health Organisation (WHO) (2023) C_WHO

Lateral-flow rapid diagnostic tests (RDTs) continue to play a vital role in global health in the management and diagnosis of infectious diseases, including malaria, HIV and COVID-19. Visually interpreted RDTs, more than any other class of diagnostics, fulfil WHO’s ASSURED criteria,1 enabling their... more

Download (97)

View PDF (363)

DNDi Strategic Plan 2021-2028 | DNDi - English version

DNDi - Drugs for neglected diseases initiative (2023) C2

Accessed on 04.04.2023 The Drugs for Neglected Diseases initiative (DNDi) is an international non-profit organization that discovers, develops, and delivers safe, effective, and affordable treatments for the most neglected patients

Download (92)

View PDF (78)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (3)

View PDF (3)

Management of Type 2 Diabetes Mellitus

Richardson, C.R.; Borgeson, J. R.; Harrison, V.; et al. National Library of Medicine (2021) CC2

The document "Management of Type 2 Diabetes Mellitus" provides comprehensive guidelines for the diagnosis, prevention, and treatment of type 2 diabetes in adults. It emphasizes the importance of individualized glycemic targets, lifestyle interventions like diet and exercise, and the use of medicatio... more

European Union Standards for Tuberculosis Care 2017 Update recommended

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis recommended

Management of Diabetes Mellitus-Tuberculosis recommended

Information and Advice for the Home: Be coronavirus safe recommended

Administration of Nirmatrelvir-ritonavir for COVID-19 recommended

European Union Standards for Tuberculosis Care 2017 Update
recommended

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis
recommended

Management of Diabetes Mellitus-Tuberculosis
recommended

Information and Advice for the Home: Be coronavirus safe
recommended

Administration of Nirmatrelvir-ritonavir for COVID-19
recommended